about
Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmissionComparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotypingPredictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.Prevalence of anal human papillomavirus infection and cytologic abnormalities among HIV-infected and HIV-uninfected men who have sex with men.Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance.Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.Inguinal and anorectal Lymphogranuloma Venereum: a case series from a sexually transmitted disease center in Rome, Italy.Perceptions of Human Papillomavirus (HPV) infection and acceptability of HPV vaccine among men attending a sexual health clinic differ according to sexual orientation.Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study.Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study groupVirological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1.Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).Prevalence and determinants of oral infection by Human Papillomavirus in HIV-infected and uninfected men who have sex with men.Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.Anal human papillomavirus in HIV-uninfected men who have sex with men: incidence and clearance rates, duration of infection, and risk factors.HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence.Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE).Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection.Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse EventsComparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients.HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects.Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (AtazanaEvolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010.Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.Long-term follow-up of nevirapine-treated patients in a single-centre cohort.Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy.Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients.Anal cytological lesions and HPV infection in individuals at increased risk for anal cancer.
P50
Q27316777-8D1272FE-FC23-4846-BE80-C5581B437F0AQ34008448-93FC79F1-8F23-492A-8CA4-1A5CA5DEA1D6Q34474961-C8A0650A-6F13-44AA-99C6-D889284BBC97Q34476753-12D2F23E-87DF-472D-A689-E81E98FEBD85Q34476934-8E67876C-694A-4F48-B558-390616B63EDFQ34477033-EA3434A4-D23A-47CB-B6C7-78FD8425FE3FQ34729027-B130A5DC-F2B3-41A9-98E4-3281037CC23FQ36102240-C1DA49DA-1CA6-48D4-BC1F-23C5EC2D5764Q36391744-6E95D8EE-0BCB-494A-B93C-03F2F64D2161Q37135207-CFFC8D0F-0EB5-4E5A-9F72-DE29B01B5BCAQ37308894-42A83C41-DA00-40CE-B437-483589EDB02CQ37355492-21BDDABF-19EF-401D-B334-C93BFC3D7101Q37501229-1EF2ABE3-EDB2-45BE-836A-CD8154C14F94Q37530942-F6B61840-8CC0-4EF4-85FA-84ABE4F621B3Q38451338-839C5840-499A-4AC3-8F27-DC7318901500Q38972140-4CE0CCB6-8833-40A6-891B-A5B7142C1816Q40046262-C37798FE-6822-4890-9E8A-5861079BE1B8Q40395175-318D0E49-5DB1-49F6-8A3E-9711726FC0CEQ40554703-F740609B-4A44-4774-9B2C-628DF78C6C45Q40608676-ECCB3BE8-F67B-40C5-A907-EB2A94801418Q40674222-9E3477A8-1CD4-4ED4-9C79-E2F0ECAA09E9Q41021229-B7C02B26-7F06-44FA-8C97-86BE7F37D693Q41056086-E5EE2B88-F707-4BAF-BC76-7A1D3B3E2C2AQ41600626-AC125903-860B-46FC-979D-680AF4EDEC34Q42228170-CEEAE05B-BE65-4018-A56C-F0AF1C3AE8AFQ42242935-270BBC16-3E0C-4F57-B91D-917E892EC198Q42255781-604E4AC0-4160-4F68-BB85-D2129954CF53Q42265061-E4A4E4A7-6A76-4A43-B56D-8F5A8542E07BQ42271285-880CFCB8-465A-4291-A396-57D341485D36Q42276740-DF37D6D4-02C8-4CF4-AC6F-98B089280AF1Q43461452-A90AE57D-E4D6-4A8E-9CBD-DE1A8D13C3A0Q43512040-61320C50-A7BD-42C0-B69D-23A705C5F7BDQ43856664-6DEDC10A-166A-4A74-AD9C-F1A6CD8D7B1BQ44553477-8D18CD36-E923-48B0-9408-614D8A3F3CDFQ44553962-2C65B030-0AFA-4B0C-BACA-8477BD502989Q45170011-2303E55B-86EB-4002-A7DC-C8037C574088Q45352431-B99A8986-C3A9-4020-9E03-8543CDF728B4Q46792927-DC3741A2-993A-483E-A2FE-7A00CC66B633Q48632654-5AA1623E-6F15-43F0-9F92-4C8701B1FD5BQ54228266-FD17CD13-B778-44E5-88E4-CAA6359B9932
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Manuela Colafigli
@ast
Manuela Colafigli
@en
Manuela Colafigli
@es
Manuela Colafigli
@nl
Manuela Colafigli
@sl
type
label
Manuela Colafigli
@ast
Manuela Colafigli
@en
Manuela Colafigli
@es
Manuela Colafigli
@nl
Manuela Colafigli
@sl
prefLabel
Manuela Colafigli
@ast
Manuela Colafigli
@en
Manuela Colafigli
@es
Manuela Colafigli
@nl
Manuela Colafigli
@sl
P106
P21
P31
P496
0000-0003-1610-6347